Mirum Pharmaceuticals (MIRM)

• Market cap: $3.67B
• 1 day: 3.16%
• 5 days: 4.89%
• 1 month: -2.51%
• 3 months: 10.2%
• 6 months: 60.94%
• Year to date: 69.93%
• 1 year: 54.43%
• 5 years: 253.84%
• 10 years: 440.8%
• Sector: Healthcare
• Industry: Biotechnology

About: Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Employees: 355